Unicycive Therapeutics, Inc. (UNCY)
NASDAQ · Healthcare
$5.45+1.30%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $115.62M
- P/E ratio
- —
- EPS
- —
- Volume
- 639,014
- 52-week high
- —
- 52-week low
- —
- Open
- $5.34
- Day high
- $5.48
- Day low
- $5.24
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$26.56M | -$1.67 |
| 2024 | — | -$36.73M | -$5.65 |
| 2023 | $675K | -$30.54M | -$1.28 |
| 2022 | $951K | -$18.06M | -$1.20 |
| 2021 | — | -$10.02M | -$0.86 |
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
- CEO
- Shalabh K. Gupta
- Employees
- 21
- Country
- US
- IPO date
- Jul 12, 2021
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Unicycive Therapeutics, Inc.'s stock price today?
- UNCY is trading at $5.45 as of Jul 20, 2026.
- What is Unicycive Therapeutics, Inc.'s market cap?
- Unicycive Therapeutics, Inc. (UNCY) has a market capitalization of $115.62M.
- Does Unicycive Therapeutics, Inc. pay a dividend?
- Unicycive Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Unicycive Therapeutics, Inc. in?
- Unicycive Therapeutics, Inc. operates in the Healthcare sector.